RedShift BioAnalytics

OverviewSuggest Edit

RedShift BioAnalytics is developing powerful new analytical tools for the R&D, life science and biopharmaceutical markets. Our measurement solutions combine tunable lasers, microfluidics, and analytical technologies to achieve revolutionary improvements in performance and measurement capabilities. 
RedShift BioAnalytics has developed a powerful new analytical technique called Microfluidic Modulation System, or MMS, that at long last enables the optical detection of very low levels of analytes in fluids. When applied to the detection of protein therapeutics, MMS provides the direct measurement, at the native concentrations, of a protein’s underlying biophysical structures. By harnessing the optical power and tunability of lasers, and the precision of fluidic modulation, MMS can rapidly measure a protein sample and its reference buffer in a single microfluidic cell.
At RedShift, our mission is to provide customers with solutions that accelerate product discovery, development and manufacturing timelines while enabling dramatic improvements in performance, efficiency and cost.

TypePrivate
Founded2005
HQBurlington, MA, US
Websiteredshiftbio.com

Latest Updates

Employees (est.) (Jan 2022)37
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at RedShift BioAnalytics

Julien Bradley

Julien Bradley

Chief Executive Officer
Eugene Ma

Eugene Ma

Chief Technology Officer
Dennis Merrill

Dennis Merrill

Vice President, Engineering & Product Development
Richard Sharp

Richard Sharp

VP of Engineering
Steve Klose

Steve Klose

Vice President, Sales
Show more

RedShift BioAnalytics Office Locations

RedShift BioAnalytics has an office in Burlington
Burlington, MA, US (HQ)
131 Middlesex Turnpike
Show all (1)

RedShift BioAnalytics Financials and Metrics

Summary Metrics

Founding Date

2005

RedShift BioAnalytics total Funding

$27.8 m

RedShift BioAnalytics latest funding size

$11 m

Time since last funding

5 years ago

RedShift BioAnalytics investors

RedShift BioAnalytics's latest funding round in March 2017 was reported to be $11 m. In total, RedShift BioAnalytics has raised $27.8 m
Show all financial metrics

RedShift BioAnalytics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

RedShift BioAnalytics Online and Social Media Presence

Embed Graph

RedShift BioAnalytics Blogs

RedShift BioAnalytics Closes $20M Series E Funding Led by Illumina Ventures

RedShift BioAnalytics Closes $20M Series E Funding Led by Illumina Ventures Financing proceeds will support continued commercial expansion, development of new applications, and product development. Burlington, MA – October 18th, 2021  RedShift BioAnalytics Inc. (RedShiftBioⓇ), a company providing ne…

RedShift BioAnalytics Celebrates Opening of StructIR Scientific Services Lab with the Launch of the StructIR Lab Grant Program

October 06, 2021 09:00 AM Eastern Daylight Time BURLINGTON, Mass.–(BUSINESS WIRE)–RedShift BioAnalytics (RedShiftBio), a company providing next-generation platform technology enabling measurements of previously undetectable structure changes in biomolecules, announced the opening of their scientific…

RedShift BioAnalytics Appoints Amol Chaubal, CFO of Waters Corporation, to Board of Directors

Burlington, MA- Sept 7th,  2021 RedShift BioAnalytics (RedShiftBio), a company providing next-generation platform technology enabling measurements of previously undetectable structure changes in biomolecules, announced the appointment of Amol Chaubal to its Board of Directors. Chaubal is Chief Finan…

An Interview with Sandeep Kondaveeti, Research and Development Scientist at Teva Pharmaceuticals

We sat down over a virtual cup of coffee to interview Sandeep Kondaveeti, Research and Development Scientist at Teva Pharmaceuticals. His research expertise is in synthesis and characterization of inorganic / organic compounds, nano-materials, and protein complexes. Editor: I understand you currentl…

The AQS3pro – A Hit For The Second Year Running at PEGS Europe

Lisbon Portugal hosted the European PEGS conference. This is the largest European event covering all aspects of protein and antibody engineering. Over 1300 attendees gathered to learn about the latest advances in protein and antibody engineering. This was the second year we showcased the next genera…

Accelerating Novel And Complex Modules Towards CMC Success

The 2020 Well Characterized Biologics and Biological Assays conference has just concluded. The agenda focused on practical advice for ensuring CMC success using characterization strategies. Most attendees we spoke with were interested in exploring alternative technologies to circular dichroism and F…
Show more

RedShift BioAnalytics Frequently Asked Questions

  • When was RedShift BioAnalytics founded?

    RedShift BioAnalytics was founded in 2005.

  • Who are RedShift BioAnalytics key executives?

    RedShift BioAnalytics's key executives are Julien Bradley, Eugene Ma and Dennis Merrill.

  • How many employees does RedShift BioAnalytics have?

    RedShift BioAnalytics has 37 employees.

  • Who are RedShift BioAnalytics competitors?

    Competitors of RedShift BioAnalytics include Halo Labs, Labconco and China Pharma Holdings.

  • Where is RedShift BioAnalytics headquarters?

    RedShift BioAnalytics headquarters is located at 131 Middlesex Turnpike, Burlington.

  • Where are RedShift BioAnalytics offices?

    RedShift BioAnalytics has an office in Burlington.

  • How many offices does RedShift BioAnalytics have?

    RedShift BioAnalytics has 1 office.